A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE

Simon D. Roger; Sarbjit V. Jassal; Michael C. Woodward; Steven Soroka; Lawrence P. McMahon

doi:10.1007/s11255-013-0512-1

A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE

Simon D. Roger, Sarbjit V. Jassal, Michael C. Woodward, Steven Soroka, Lawrence P. McMahon

Résultat de recherche: Article › examen par les pairs

17 Citations (Scopus)

Résumé

Background: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. Methods: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11.0 g/dL were randomised to darbepoetin alfa (n = 28) or placebo (n = 23). HRQOL was measured using a number of instruments including Short Form-36 (SF-36) and Functional Assessment of Cancer Therapy-Anaemia (FACT-An). Results: The primary endpoint, mean SF-36 Vitality Score at Week 24, was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups. Darbepoetin alfa-treated patients experienced statistically significant improvements in some SF-36 and FACT-An Subscale Scores. Mean Hb was higher with darbepoetin alfa (12.5 [12.1, 12.9] g/dL) than with placebo (10.5 [10.1, 11.0] g/dL). The safety profiles were comparable between the treatment groups. The study was limited by only 20 % of the planned patient recruitment being achieved. Conclusions: Darbepoetin alfa increased Hb and, within study limitations, suggested that improvements in some HRQOL domains in older CKD patients with anaemia may be achieved with more physiological haemoglobin.

Langue d'origine	English
Pages (de-à)	469-475
Nombre de pages	7
Journal	International Urology and Nephrology
Volume	46
Numéro de publication	2
DOI	https://doi.org/10.1007/s11255-013-0512-1
Statut de publication	Published - févr. 2014
Publié à l'externe	Oui

Note bibliographique

Funding Information:
Conflict of interest S.D.R. has received research funding from Amgen, Janssen-Cilag, La Hoffman Roche and Affymax. S.V.J. has received research funding from Ortho Biotech and speaker honoraria from Amgen, Ortho Biotech and Pfizer. S.D.S. has received research funding from Amgen, Roche and Merck. M.C.W. has no conflicts of interest relevant to this article. L.P.M. has accepted research grants from Amgen.

Funding Information:
Acknowledgments The authors wish to thank the participating dialysis centres and investigators for contributions to the study and data collection—Drs Stephen Chow, Serge Cournoyer, Robert Fas-sett, Margaret Fraenkel, Marc Ghannoum, Helen Healy, Ashley Irish, Garth Mortis, Danny Sapir and Andrew Steele. This study was funded and sponsored by Amgen Australia Pty Ltd and Amgen Canada Inc. Data analysis was performed by Dave Carter, Nicola Hogan and Julie-Ann Quayle. Editorial assistance was provided by Yoonah Choi of Evidencia Medical Communications Pty Ltd, contracted by Amgen Australia Pty Ltd.

ASJC Scopus Subject Areas

Nephrology
Urology

PubMed: MeSH publication types

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1007/s11255-013-0512-1

Autres fichiers et liens

Empreinte numérique

Plonger dans les sujets de recherche 'A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE'. Ensemble, ils forment une empreinte numérique unique.

Citer

A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE. / Roger, Simon D.; Jassal, Sarbjit V.; Woodward, Michael C. et al.
Dans: International Urology and Nephrology, Vol. 46, N° 2, 02.2014, p. 469-475.

Résultat de recherche: Article › examen par les pairs

@article{0d802f20dbfb437f9f0da14f056ba953,

title = "A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp{\textregistered} (darbepoetin alfa) in older people: STIMULATE",

abstract = "Background: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. Methods: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11.0 g/dL were randomised to darbepoetin alfa (n = 28) or placebo (n = 23). HRQOL was measured using a number of instruments including Short Form-36 (SF-36) and Functional Assessment of Cancer Therapy-Anaemia (FACT-An). Results: The primary endpoint, mean SF-36 Vitality Score at Week 24, was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups. Darbepoetin alfa-treated patients experienced statistically significant improvements in some SF-36 and FACT-An Subscale Scores. Mean Hb was higher with darbepoetin alfa (12.5 [12.1, 12.9] g/dL) than with placebo (10.5 [10.1, 11.0] g/dL). The safety profiles were comparable between the treatment groups. The study was limited by only 20 % of the planned patient recruitment being achieved. Conclusions: Darbepoetin alfa increased Hb and, within study limitations, suggested that improvements in some HRQOL domains in older CKD patients with anaemia may be achieved with more physiological haemoglobin.",

author = "Roger, {Simon D.} and Jassal, {Sarbjit V.} and Woodward, {Michael C.} and Steven Soroka and McMahon, {Lawrence P.}",

note = "Funding Information: Conflict of interest S.D.R. has received research funding from Amgen, Janssen-Cilag, La Hoffman Roche and Affymax. S.V.J. has received research funding from Ortho Biotech and speaker honoraria from Amgen, Ortho Biotech and Pfizer. S.D.S. has received research funding from Amgen, Roche and Merck. M.C.W. has no conflicts of interest relevant to this article. L.P.M. has accepted research grants from Amgen. Funding Information: Acknowledgments The authors wish to thank the participating dialysis centres and investigators for contributions to the study and data collection—Drs Stephen Chow, Serge Cournoyer, Robert Fas-sett, Margaret Fraenkel, Marc Ghannoum, Helen Healy, Ashley Irish, Garth Mortis, Danny Sapir and Andrew Steele. This study was funded and sponsored by Amgen Australia Pty Ltd and Amgen Canada Inc. Data analysis was performed by Dave Carter, Nicola Hogan and Julie-Ann Quayle. Editorial assistance was provided by Yoonah Choi of Evidencia Medical Communications Pty Ltd, contracted by Amgen Australia Pty Ltd.",

year = "2014",

month = feb,

doi = "10.1007/s11255-013-0512-1",

language = "English",

volume = "46",

pages = "469--475",

journal = "International Urology and Nephrology",

issn = "0301-1623",

publisher = "Springer Netherlands",

number = "2",

}

TY - JOUR

T1 - A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people

T2 - STIMULATE

AU - Roger, Simon D.

AU - Jassal, Sarbjit V.

AU - Woodward, Michael C.

AU - Soroka, Steven

AU - McMahon, Lawrence P.

N1 - Funding Information: Conflict of interest S.D.R. has received research funding from Amgen, Janssen-Cilag, La Hoffman Roche and Affymax. S.V.J. has received research funding from Ortho Biotech and speaker honoraria from Amgen, Ortho Biotech and Pfizer. S.D.S. has received research funding from Amgen, Roche and Merck. M.C.W. has no conflicts of interest relevant to this article. L.P.M. has accepted research grants from Amgen. Funding Information: Acknowledgments The authors wish to thank the participating dialysis centres and investigators for contributions to the study and data collection—Drs Stephen Chow, Serge Cournoyer, Robert Fas-sett, Margaret Fraenkel, Marc Ghannoum, Helen Healy, Ashley Irish, Garth Mortis, Danny Sapir and Andrew Steele. This study was funded and sponsored by Amgen Australia Pty Ltd and Amgen Canada Inc. Data analysis was performed by Dave Carter, Nicola Hogan and Julie-Ann Quayle. Editorial assistance was provided by Yoonah Choi of Evidencia Medical Communications Pty Ltd, contracted by Amgen Australia Pty Ltd.

PY - 2014/2

Y1 - 2014/2

N2 - Background: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. Methods: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11.0 g/dL were randomised to darbepoetin alfa (n = 28) or placebo (n = 23). HRQOL was measured using a number of instruments including Short Form-36 (SF-36) and Functional Assessment of Cancer Therapy-Anaemia (FACT-An). Results: The primary endpoint, mean SF-36 Vitality Score at Week 24, was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups. Darbepoetin alfa-treated patients experienced statistically significant improvements in some SF-36 and FACT-An Subscale Scores. Mean Hb was higher with darbepoetin alfa (12.5 [12.1, 12.9] g/dL) than with placebo (10.5 [10.1, 11.0] g/dL). The safety profiles were comparable between the treatment groups. The study was limited by only 20 % of the planned patient recruitment being achieved. Conclusions: Darbepoetin alfa increased Hb and, within study limitations, suggested that improvements in some HRQOL domains in older CKD patients with anaemia may be achieved with more physiological haemoglobin.

AB - Background: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. Methods: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11.0 g/dL were randomised to darbepoetin alfa (n = 28) or placebo (n = 23). HRQOL was measured using a number of instruments including Short Form-36 (SF-36) and Functional Assessment of Cancer Therapy-Anaemia (FACT-An). Results: The primary endpoint, mean SF-36 Vitality Score at Week 24, was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups. Darbepoetin alfa-treated patients experienced statistically significant improvements in some SF-36 and FACT-An Subscale Scores. Mean Hb was higher with darbepoetin alfa (12.5 [12.1, 12.9] g/dL) than with placebo (10.5 [10.1, 11.0] g/dL). The safety profiles were comparable between the treatment groups. The study was limited by only 20 % of the planned patient recruitment being achieved. Conclusions: Darbepoetin alfa increased Hb and, within study limitations, suggested that improvements in some HRQOL domains in older CKD patients with anaemia may be achieved with more physiological haemoglobin.

UR - http://www.scopus.com/inward/record.url?scp=84896708929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896708929&partnerID=8YFLogxK

U2 - 10.1007/s11255-013-0512-1

DO - 10.1007/s11255-013-0512-1

M3 - Article

C2 - 23982766

AN - SCOPUS:84896708929

SN - 0301-1623

VL - 46

SP - 469

EP - 475

JO - International Urology and Nephrology

JF - International Urology and Nephrology

IS - 2

ER -